The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.
Read More
Many patients report that marijuana improves their pain. Their experience has a grain of truth to it, but not enough to classify cannabis as an analgesic.
Read More
The FDA rarely issues absolute contraindications, but that’s where their language is tilting in a new warning on Z-Hypnotics. We look at the data behind their decision and offer six tips for safer prescribing of sleep medications.
Read More
Shawn Christopher Shea, MD has been fine-tuning the art of doctor-patient communications for over 30 years. He shares his tips on talking about medications.
Read More
Dubbed “California Rocket Fuel” by Stephen Stahl, the combination of venlafaxine and mirtazapine seemed to hit all the right receptors. The hype may have gotten a little ahead of the evidence on this one, however, as three new studies reveal. Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
